SCHEMBL2865429

SCHEMBL2865429

O=C(NC(=S)Nc1cccc(Oc2ccccc2)c1)c1cccnc1CN1CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
EPHX2 P34913 2/20 0.46
MCHR1 Q99705 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
MAPT P10636 2/20 0.45
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
KDR P35968 1/20 0.45
HPGD P15428 3/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.43
TACR2 P21452 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2869847 0.86 EPHX2 (0.51) EPHX2MCHR1KDRTACR2
SCHEMBL2865292 0.83 HPGD (0.50) ALDH1A1MCHR1SMN1; SMN2MAPTRAB9A
SCHEMBL2867540 0.83 MAPT (0.45) ALDH1A1SMN1; SMN2MAPTRAB9ANPC1
SCHEMBL3150822 0.81 HIF1A (0.50) ALDH1A1EPHX2SMN1; SMN2MAPTRAB9A
SCHEMBL4362304 0.80 ALDH1A1 (0.64) ALDH1A1EPHX2MCHR1SMN1; SMN2MAPT
SCHEMBL2869724 0.80 KDR (0.48) ALDH1A1SMN1; SMN2MAPTRAB9ANPC1
SCHEMBL2864605 0.80 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTRAB9ANPC1
SCHEMBL14096264 0.79 KDR (0.51) ALDH1A1SMN1; SMN2MAPTRAB9ANPC1
SCHEMBL2868210 0.79 MAPT (0.51) ALDH1A1EPHX2SMN1; SMN2MAPTRAB9A
SCHEMBL2861364 0.78 MEN1 (0.54) ALDH1A1MAPTKDRHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS (US) 2009-01-22 US claimed
CN-101087755-A Substituted arylacylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS INC (US) 2007-12-12 CN claimed
EP-1747196-A2 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2007-01-31 EP claimed
WO-2006083271-A2 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2006-08-10 WO claimed
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-02-02 US claimed
US-7767706-B2 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2010-08-03 US disclosed
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS (US) 2009-01-22 US disclosed
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication PIGS, NAT1, AADAC ALDH1A1 176/4885EPHX2 2235/4885MCHR1 3804/4885
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION PIGS, NAT1, AADAC ALDH1A1 176/4885EPHX2 2235/4885MCHR1 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.